Clinical trials: Stage II Breast Cancer
Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
This study is designed to evaluate the safety, tolerability, PKharmacokinetic profile and treatment effect of pamiparib in Chinese participants with advanced high-grade ovarian cancer (including fallopian cancer or primary…
- Trial name
- NCT03333915
- Testing
- Pamiparib
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- BeiGene
Carcinoma, Breast
CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.
- Trial name
- NCT00043394
- Testing
- 0.04 mg/kg CpG 7909, Herceptin®, 0.08 mg/kg CpG 7909
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Breast Neoplasms
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.
- Trial name
- NCT00097721
- Testing
- E7389
- Where
- 16 sites in United States
- Volunteers
- 104 people
- Sponsor
- Eisai Inc.
Breast Cancer
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
This study will evaluate the efficacy and safety of treatment with oral capecitabine or intravenous (IV) 5-fluorouracil (5-FU), in combination with epirubicin and cyclophosphamide, prior to surgery in participants with breast…
- Trial name
- NCT02846428
- Testing
- 5-Fluorouracil, Capecitabine, Cyclophosphamide
- Where
- 21 sites in France
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms, Metastases, Neoplasm
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
The anticancer agent paclitaxel (marketed as Taxol) has shown remarkable activity against metastatic breast cancer. However, the Taxol formulation requires prolonged administration times, and there are safety problems that have…
- Trial name
- NCT00046514
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Celgene Corporation
Breast Cancer
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
This is a research study to evaluate the effects of ThermoDox in combination with therapeutic heating of the chest wall in the treatment of recurrent regional breast cancer.
- Trial name
- DIGNITY (NCT00826085)
- Testing
- ThermoDox in combination with Microwave Hyperthermia (heat)
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Imunon
Cancer, Neoplasms
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Conditions
- Cancer, Neoplasms, Neoplasms, Breast, Tumor
- Trial name
- NCT06819215
- Testing
- VB15010
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Neoplasms, Breast
Study Of Ispinesib In Subjects With Breast Cancer
The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is…
- Trial name
- NCT00089973
- Testing
- Ispinesib
- Where
- 13 sites in United States, Belgium and 3 more
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Advanced ER+/HER2- Breast Cancer
Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
This study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with endocrine therapy in ER+/HER2- breast…
- Trial name
- NCT07235176
- Testing
- QLS1304 tablet+Fulvestrant or QLC1401, QLS1304 tablet+Fulvestrant，AI or QLC1401+CDK4/6i
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Locally Recurrent or Metastatic Breast Cancer
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or…
- Trial name
- NCT01256762
- Testing
- Imetelstat sodium, Bevacizumab, Paclitaxel
- Where
- 55 sites in United States, Canada
- Volunteers
- 166 people
- Sponsor
- Geron Corporation